Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.
Minoxidil may not be effective due to low sulfotransferase activity, and the user considers adding tretinoin to the regimen. They are unsure about the timing and combination with microneedling.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.
A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.
A 44-year-old experienced hair regrowth after a snowboarding injury using detox, diet changes, vitamins, collagen, krill oil, and scalp massages, without Minoxidil or finasteride. Another person was skeptical, suggesting these methods may not work for everyone.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
Exosome therapy for hair loss is questioned for its effectiveness and authenticity. Users express skepticism, citing manipulated photos and high costs.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
KX-826 is being considered as a potential alternative to finasteride for hair loss, but it is not expected to be more effective. Combining KX-826 with finasteride and minoxidil may provide better results than using it alone.
Joel McHale had four hair transplants and likely uses finasteride to maintain his hair. The discussion included personal experiences and side effects of hair loss treatments.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.
The conversation discusses hair regrowth after 5 months of using finasteride and minoxidil, along with 3 sessions of laser therapy and exosomes. The user is hopeful about regaining their bangs.
A user shared their positive experience with Musely's Modern Hair Formula and Classic Combo for hair regrowth, highlighting ingredients like IPCs and Exosomes. They offered a $50 gift card for the product, leading to skepticism from others about the promotion.
Adding creatine while using finasteride and minoxidil caused skin irritation and hair thinning. Creatine may affect DHT levels, leading to these issues.
Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.
Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.
The user has been experiencing aggressive hair loss despite using finasteride, minoxidil, dutasteride, ketoconazole, and derma rolling. Suggestions include continuing current treatments, considering RU58841, checking for deficiencies, and possibly trying collagen supplements or oral minoxidil.
Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.
The user shared progress photos of hair regrowth using copper peptides and NAD+ over five months. Another user commented on the lighting, and another praised the progress.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
Using a low dose of topical Tamoxifen effectively reduces gynecomastia caused by finasteride, with minimal side effects. The solution involves mixing Tamoxifen with ethanol and propylene glycol, applied daily to the chest.
The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.
A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
A user reported success with RU58841 and a 1mm derma roller for hair regrowth, noting significant improvement in hair density and reduced scalp visibility. They also mentioned using minoxidil and black castor oil in the past, with mixed results.
The conversation discusses the use of AlphaInfuse, a micro-infusion system with Panax ginseng and Eclipta prostrata extracts, for hair growth and its comparison to Minoxidil. The original poster seeks personal experiences and evidence of its effectiveness.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.